A Coruna

• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Heart Failure study with Danicamtiv in patients with reduced heart function caused by gene mutation Ended
  2023-505492-68-00 4 2020-10-06 Primary Dilated Cardiomyopathy Due to Either MYH7 o TTN Variants
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult P … Ended
  2023-505125-14-00 4 2020-07-24 Acute Traumatic Cervical Spinal Cord Injury
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended
  2023-506527-28-00 5 2020-06-29 Axial Spondyloarthritis
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syn … Ended
  2024-512448-41-00 5 2020-04-01 Bronchiolitis Obliterans Syndrome in Patients post Single or post Doub
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended
  2023-506528-95-00 5 2019-11-21 Psoriatic Arthritis
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended
  2023-503956-29-00 5 2019-08-26 Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient M
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable Ended
  2024-513731-24-00 4 2019-05-14 Non-small cell lung cancer (NSCLC)
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended
  2023-508757-75-00 5 2017-09-18 Stage IV Non-Small Cell Lung Cancer (NSCLC)
• CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended
  2022-501784-40-00 5 2017-05-26 Untreated Unresectable or Metastatic Urothelial Cancer
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg … Ended
  2024-516132-10-00 4 2016-02-05 Metastatic breast cancer
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce

Showing 529–552 of 558 trials